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Cytotoxic Hydrogen Bridged Ruthenium Quinaldamide Complexes 
Showing Induced Cancer Cell Death by Apoptosis 
Rianne M. Lord,
a*
 Simon J. Allison,
b
 Karen Rafferty,
a
 Laura Ghandhi,
a
 Christopher M. Pask
a
 and 
Patrick C. McGowan
a* 
This report presents the first known p-cymene ruthenium quinaldamide complexes which are stablized by a hydrogen-
bridging atom, [[{(p-cym)RuIIX(N,N)}{H+}{(N,N)XRuII(p-cym)}][PF6] (N,N = functionalised quinaldamide and X = Cl or Br). 
These complexes are formed by a reaction of [p-cymRu(-X)2]2 with a functionalised quinaldamide ligand. When filtered 
over NH4PF6, and under aerobic conditions the equilibrium of NH4PF6  NH3 + HPF6 enables incorporation of HPF6 and the 
stabilisation of two monomeric ruthenium complexes by a bridging H+, which are counter-balanced by a PF6 counterion. X-
ray crystallographic analysis is presented for six new structures with O···O distances of 2.430(3)-2.444(17) Å, which is 
significant for strong hydrogen bonds. Chemosensitivity studies against HCT116, A2780 and cisplatin-resistant A2780cis 
human cancer cells showed the ruthenium complexes with a bromide ancillary ligand to be more potent than those with a 
chloride ligand. The 4'-fluoro compounds show a reduction in potency for both chloride and bromide complexes against all 
cell lines, but an increase in selectivity towards cancer cells compared to non-cancer ARPE-19 cells, with a selectivity index 
> 1. Mechanistic studies showed a clear correlation between IC50 values and induction of cell death by apoptosis. 
Introduction 
There are only a small number of reports on the synthesis and 
isolation of transition metal hydrogen-bridging complexes. 
Usually solvent molecules provide the H
+
 source and few 
researchers suggest the possibility of the reagent NH4PF6 
providing the source of H
+
. Peacock et al. were amongst the 
first to isolate and characterise by X-ray crystallographic 
analysis, cobalt, manganese and chromium hydrogen-bridged 
structures, [Co
III
(L·H3L)Co
III
][PF6]3,
1
 [Mn
II
(L·H3L)Mn
IV
]][PF6]3,
2
 
and [Cr
III
(L·H3L)Cr
III
][PF6]3,
3
 (LH3 = N,N’,N”-tris[(2S)-2-
hydroxypropyl]-1,4,7-triazacyclononane) respectively. Some of 
these compounds have been studied using circular dichroism, 
magnetic susceptibility and cyclic voltammetry, in order to 
understand their spin states and oxidation states.
2
 Ward et al. 
have also synthesised and characterised by X-ray 
crystallographic analysis nickel and copper hydrogen-bridged 
structures, [Ni
II
(L·HL)]2[PF6]2,
4
 (L = 6-(2-hydroxyphenyl)-2,2’-
bipyridine) and [Cu
II
(L
2
)]·(HPF6)0.5·H2O,
5
 (L = 6,6’-bis(2-
hydroxyphenyl)-2,2’-bipyridine) respectively. All these 
compounds have a shortened O···O bond distance, averaging 
2.34 Å, indicative of strong hydrogen-bonds. In all cases, the 
hydrogen atoms could not be located in the crystal structures; 
however their presence is needed in order to balance the PF6 
counterions. Nothing has yet been reported on the possible 
applications of such compounds, therefore we report here the 
application of hydrogen-bridged ruthenium complexes as 
possible anti-cancer agents. 
In a search for less toxic and more potent alternatives to 
cisplatin, organometallic complexes have shown promising 
activity as anti-cancer agents.
6-16
 Ruthenium-based complexes 
are some of the most promising, with reported selective 
potency in vitro and in vivo.
17-22 
McGowan et al. have 
synthesised a range of ruthenium metal complexes for their 
uses as anticancer agents.
23-26
 The work published on 
ruthenium quinaldamides showed that under inert 
atmosphere conditions, the filtering over NH4PF6 yielded the 
ruthenium quinaldamide monomers.
27
 The use of dry 
conditions avoids the hydrolysis of NH4PF6 to NH3 and HPF6. 
These monomeric complexes show low IC50 values against a 
range of cell lines and also form adducts with guanine 
nucleotides. Herein, we present the same synthetic strategy 
using aerobic conditions and show that the monomers are no 
longer stable under these conditions and the HPF6 present 
from the hydrolysis of NH4PF6, stabilises two ruthenium 
quinaldamide species, [{(p-cym)Ru
II
X(N,N)}{H
+
}{(N,N)XRu
II
(p-
cym)}][PF6], with incorporation of HPF6. This motif has 
previously been reported for our ruthenium picolinamide 
complexes, in which an average O···O bond distance of 2.43 Å 
was observed.
17
 The X-ray crystallographic data was reported, 
however, chemosensitivity studies were not determined. 
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Herein, chemosensitivity studies have been carried out against 
HCT116 (human colon carcinoma), A2780 (human ovarian 
carcinoma) and A2780cis (cisplatin resistant A2780) cancer cell 
lines, and against non-cancer ARPE-19 (human retinal 
epithelium) cells. Studies investigated whether the complexes 
might induce apoptosis (programmed cell death), a cell death 
mechanism that is commonly suppressed in cancers. This was 
measured in the HCT116 cancer cells by loss of mitochondrial 
membrane potential which is an early marker of apoptosis. 
Cell images by phase contrast microscopy at various time-
points after compound addition suggested induction of cell 
death rather than growth arrest. Apoptotic analyses revealed a 
clear correlation between chemosensitivity and levels of 
apoptosis, whereby the most active compound induces the 
highest percentage of apoptosis. 
Results and discussion 
Using a modification of the previously established literature 
method by Bennett et al.,
28, 29
 the ruthenium(II) p-cymene 
halide complexes were synthesised by dissolving Ru
III
X3.xH2O 
(X = Cl or Br) and -terpinene in ethanol, then heating to reflux 
for 16 hours. The resulting dark red powder was filtered and 
washed with ice cold ethanol to yield the desired starting 
ruthenium p-cymene dimer. Upon addition of two equivalents 
of a substituted quinaldamide in ethanol and filtering over 
NH4PF4, the reaction mixture formed a pale orange precipitate 
and yielded complexes 1-6 as analytically pure products 
(Scheme 1). Single orange-red crystals suitable for X-ray 
crystallographic analysis were obtained for complexes 1-6. 
They crystallised in either a triclinic P1 (1-3, 5-6) or 
monoclinic C2/c (4) space group. All of the angles around the 
metal centre show the geometry expected for pseudo 
octahedral compounds which is common for half-sandwich 
“piano-stool” structures (Tables 1). The angles between the 
metal and bidentate ligands are in the range 75.4(2)-87.5(3)°, 
with the remaining three coordination sites occupied by the p-
cymene ligand, with the angles observed for their centroids to 
the halide or bidentate ligand ranging between 126.81-
134.78°. Molecular structures for complexes 1-6 are shown in  
Scheme 1 Synthetic route for the synthesis of ruthenium quinaldamide 
complexes 1-6 via addition of a functionalised quinaldamide ligand to [p-
cymRuX(-X)]2. 
Figure 1, with displacement ellipsoids placed at the 50% 
probability level and hydrogen atoms and PF6 anions omitted 
for clarity. The proton bridging between the two carbonyl 
oxygens provides the +1 charge, which is counter-balanced by 
the PF6 anion, and both metal centres are in their +2 oxidation 
state. The two such monomer units [p-cymRu
II
(N,N)X] are held 
together by one intermolecular hydrogen bond which links 
O(1) and O(1’). The short O···O distances of 2.439(3)-2.444(17) 
Å (Table 2), which are only slightly longer than double of a 
typical O-H distance, are at the lower limit for a pair of 
hydrogen-bonded oxygen atoms, indicative of strong hydrogen 
bonds. This was also reported for nickel complexes synthesised 
by Ward et al., in which they observed O···O distances of 2.37-
2.39 Å.
4, 30,
 
31
 However, weak asymmetric O-H···O hydrogen 
bonds more typically have O···O distance > 2.7 Å.
32
 As shown in 
the previously reported structures by Ward et al.,
4
 the 
hydrogen-bridging complexes are further stabilized by 
intermolecular interactions. The packing diagrams for 
complexes 1-6 are presented in Figures S1-2, and show that 
these ruthenium quinaldamide complexes have several 
intramolecular and intermolecular interactions (Table S1a-f), 
which could also contribute to the stability of the dimers. All 
the complexes have their aromatic quinaldamide rings brought 
into close proximity, with relatively short π-π stacking 
interactions of 3.753-3.919 Å. X-ray crystallographic data is 
also presented in the supplementary information (Table S2). 
Table 1 Selected bond lengths (Å) and bond angles (°) for complexes 1-6, with s.u.s in parenthesis  
Bond Length (Å) 1 2 3 4 5 6 
Ru(1)-N(1) 2.100(2)/2.035(2) 2.130(2) 2.0800(18) 2.079(2) 2.130(3) 2.076(3) 
Ru(1)-N(2) 2.1222(19)/2.113(2) 2.076(2) 2.1368(18) 2.136(2) 2.085(3) 2.123(3) 
Ru(1)-X(1) 2.3854(6)/2.4093(9) 2.3969(9) 2.3962(6) 2.5438(5) 2.5328(5) 2.5402(5) 
Ru(1)-Cg(4) 1.6735(10)/1.6954(12) 1.6803(12) 1.6814(9) 1.7006(14) 1.6930(18) 1.6953(17) 
Bond Angles (°) 1 2 3 4 5 6 
N(1)-Ru(1)-N(2) 75.42(8)/76.99(8) 76.10(8) 76.00(7) 76.32(9) 76.13(11) 76.52(11) 
N(1)-Ru(1)-X(1) 86.47(2)/87.29(6) 86.15(6) 87.76(5) 86.94(6) 85.89(8) 87.03(8) 
N(2)-Ru(1)-X(1) 83.65(6)/83.26(6) 87.61(7) 86.32(5) 84.45(6) 87.50(8) 84.03(8) 
N(1)-Ru(1)-Cg(4) 126.83(7)/129.68(8) 132.47(8) 128.18(6) 128.78(7) 132.41(10) 128.46(11) 
N(2)-Ru(1)-Cg(4) 134.73(7)/133.88(7) 128.01(8) 132.57(6) 134.15(7) 128.37(10) 133.79(10) 
X(1)-Ru(1)-Cg(4) 130.53(4)/127.74(5) 128.83(5) 128.45(4) 128.12(5) 128.79(6) 128.73(7) 
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Figure 1 Molecular structures for compounds 1-6. Hydrogen atoms and PF6 anions are omitted for clarity and displacement ellipsoids are shown only for heteroatoms, 
at the 50% probability level. 
Table 2 Hydrogen bonding donor-acceptor distances (Å) for complexes 1-6 
Chemosensitivity Studies 
Chemosensitivity studies were undertaken using the MTT 
assay and IC50 values were determined against HCT116 (human 
colon carcinoma), A2780 (human ovarian carcinoma) and 
A2780cis (cisplatin resistant A2780 cells) cell lines, exposed to 
each of compounds 1-6 or cisplatin (Table 3). Against all three 
cancer cell lines the Ru-Br complexes were consistently more 
active than the Ru-Cl analogues. The 4-fluoro compounds 2 
and 5 are the least active when compared to the other fluoro 
compounds, however, changing from Ru-Cl (compound 2, 39.2 
± 0.8 M) to Ru-Br (compound 5, 8.7 ± 0.4 M) there is a > 4-
fold increase in cytotoxicity. The results show that the 2’,4’-
difluoro compounds 3 and 6 are the most active, and when 
comparing Ru-Cl (compound 3, 5.9 ± 0.2 M) and Ru-Br 
(compound 6, 3.9 ± 0.3 M) there is a 1.5-fold increase in 
cytotoxicity. They is an increase in cytotoxicity when compared  
Figure 2 The resistance factor for the compounds as indicated. This is defined as 
the IC50 in A2780cis divided by IC50 in A2780 cells. An RF of 1 indicates equal 
potency against both cell lines. An RF > 1 indicates that the A2780cis is more 
resistant than A2780. An RF < 1 indicates that the A2780cis is more sensitive 
than the A2780 cells. 
 
to the 2'-fluoro compounds 1 and 4, but to a similar degree in 
both cancer and non-cancer cells. Most of the compounds 
were more active against A2780 cells than A2780cis cells, but 
the level of resistance is much less than for that of cisplatin 
(Figure 2 and Table S3, SI). Compound 2 is the least potent but 
showed similar activity towards A2780 and A2780cis cancer 
cells, and was more active against all three cancer cell lines 
when compared to non-cancer ARPE-19 cells. The results show 
that potency is dependent on position of the fluoro.
Compound O(1)···O(1’) (Å) 
1 2.425(3) 
2 2.420(4) 
3 2.442(3) 
4 2.439(3) 
5 2.444(17) 
6 2.448(15) 
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Table 3 IC50 values (M) for cisplatin and compounds 1-6 against HCT116, A2780, A2780cis and ARPE-19 cell lines 
 IC50 values (M) ± Standard Deviation 
Compound HCT116 A2780 A2780cis ARPE-19 
Cisplatin N.D. 1.00 ± 0.16 10.6 ± 0.9 6 ± 126 
1 6.7 ± 0.5 4.8 ± 0.6 11.7 ± 0.6 4.3 ± 0.3 
2 39.2 ± 0.8 17.56 ± 1 22 ± 1 > 50 
3 5.9 ± 0.2 4.0 ± 0.5 7.4 ± 0.5 3.7 ± 0.8 
4 4.02 ± 0.11 3.2 ± 0.4 5.46 ± 0.17 3.06 ± 0.09 
5 8.7 ± 0.4 9 ± 3 14 ± 2 10.4 ± 3.3 
6 3.9 ± 0.3 3.0 ± 0.4 6.5 ± 0.9 2.9 ± 0.2 
 
substituent and increasing the number of electron 
withdrawing substituents increased the potency by > 6-fold. 
Selectivity for Cancer Cells 
One of the major limitations of existing anti-cancer drugs is 
their poor selectivity towards cancer cells, restricting the 
drugs’ dosage. As well as causing harmful side effects for the 
patient, this dose-limiting toxicity impacts upon treatment 
effectiveness. . Comparing the response of tumour cell lines to 
non-cancer ARPE-19 cells provides a preliminary indication 
oselectivity. Whilst compounds 1, 3, 4 and 6 show no 
selectivity towards cancer cells (ratio of IC50 values in ARPE-19 
cells to cancer cells ≤ 1), compounds 2 and 5 showed evidence 
of selectivity to certain cancer cells (Figure 3 and. Table S4, SI). 
Compound 2 in particular demonstrated selectivity against all 
the cancer cell lines tested with selectivity ranging from 2.85 
to 1.27 fold increased chemosensitivity towards cancer cells 
compared to ARPE-19 non-cancer cells (HCT116: 1.27; A2780: 
2.85; A2780cis: 2.29; Figure 3 and Table S3, SI). However, 
compound 2 is the least active compound against all cancer 
cell lines tested. 
Induction of Cancer Cell Death by Apoptosis 
IC50 values determined by chemosensitivity studies using the 
MTT assay indicates the concentration of drug required for a 
50% reduction in  cell number. This provides invaluable 
information about the activity of the drug against the cell line 
but does not distinguish between effects on cell proliferation 
and effects on cell survival. The observed activity of these 
compounds towards the cell lines could be caused by induction 
of cell growth arrest or the compounds may cause cell death. 
Cell images under phase contrast microscopy at various time-
points after compound addition suggested induction of cell 
death as suggested by an increase in the proportion of non-
adhered cells rather than growth arrest. Using flow cytometry 
and staining for loss of mitochondrial membrane potential the 
percentage of apoptotic cells were quantified following 
incubation of HCT116 cells with 0–60 µM of compounds 1-6 
for 72 hours (Figure 4 and Table S4, SI). 
The 2’,4’-difluoro compounds 3 and 6, which were the most 
active compounds in the MTT chemosensitivity studies, also 
induced significant levels of apoptotic cell death against 
HCT116  cancer cell lines (Figure 4 and Table S5, SI) in a dose-
responsive manner. A 72 hour exposure of HCT116 cells to 20  
Figure 3 Show the selectivity index defined as the IC50 in ARPE-19 divided by IC50 
relevant cancerous cells. An SR = 1 indicates equitoxic potency against tumour 
and normal cells. An SR > 1 indicates preferential selectivity for tumour cells 
compared to normal cells. An RF < 1 indicates poor selectivity (greater 
cytotoxicity towards ARPE cells compared to normal cells) 
 
Figure 4 % of apoptosis for control and compounds 1-6 against HCT116 cells at 
concentrations ranging from 0-60 M. 
 
M of compound 3 resulted in ~76% of cells in early stages of 
apoptosis  and compound 6 which was the most active against 
the MTT assay showed significant apoptosis, with 84% 
apoptotic cells. In contrast, compounds 2 and 5 were the least 
active compounds against the MTT assay and show the least 
amount of apoptotic cells. Compound 2 is the least active of 
this series of compounds, and a higher concentration of 60 M 
of the compound had to be used to induce apoptosis, resulting 
in only 33% apoptotic cells. Whereas the more active 
compound 5 induces apoptosis at a concentration of 20 M 
and gave 35% apoptotic cells. These observations indicate a 
clear correlation between IC50 value and levels of apoptosis 
induced. 
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Conclusions 
We report the successful synthesis of ruthenium hydrogen-
bridged complexes from the reaction of [p-cymRuX2]2 (X = Cl or 
Br) with a functionalised quinaldamide ligand. The reaction 
conditions differ from our previously synthesised ruthenium 
quinaldamide complexes, as here we utilise aerobic conditions 
and show the hydrolysis of the NH4PF6 reagent yields the 
stabilisation of these unusual H
+
 bridged complexes, counter-
balanced by a PF6 anion. These compounds have been tested 
against HCT116, A2780 and A2780cis cancer cells, and results 
show the 2’,4’-difluoro compounds 3 (X = Cl) and 6 (X = Br) are 
the most potent against all cell lines. The di-substituted 
compounds are more potent than the mono-substituted, 
showing the number and position of the fluoro group is 
important to the potency. Across all cell lines, the 4-fluoro 
compounds 2 and 5 are the least active, with >6-fold decrease 
in potency observed against HCT116 cancer cells. The most 
significant results when comparing the different ancillary 
ligands are that the chloride compounds 1-3 are general less 
active than the bromide complexes 4-6, with up >4-fold 
increase in IC50 values observed against HCT116 cells. 
Induction of cell death by apoptosis was investigated and this 
showed a clear correlation between IC50 values and levels of 
apoptosis induced. However, the results also indicate the 
importance to consider selectivity and ability to overcome 
drug resistance as well as potency with compound appearing 
the most promising by these important criteria.  
Experimental 
Materials 
All chemicals were supplied by Sigma-Aldrich Chemical Co., 
Acros Organics, Strem Chemical Co. and BOC gases. 
Functionalised quinaldamide ligands were prepared by 
adaptations of literature methods.
33
 Deuterated NMR solvents 
were supplied by Sigma-Aldrich Chemical Co. or Acros 
Organics.  
Analysis  
All NMR spectra were recorded on a Bruker DPX 300 or a 
Bruker DPX 500 spectrometer. Microanalyses were recorded at 
the University of Leeds Microanalytical Service. Mass Spectra 
were recorded on a Micromass ZMD spectrometer with 
electrospray ionisation and photoiodide array analyser at the 
University of Leeds Mass Spectrometry Service. 
X-ray Crystallography 
A suitable single crystal was selected and immersed in an inert 
oil. The crystal was then mounted on a glass capillary or nylon 
loop and attached to a goniometer head on Nonius KappaCCD 
area detector diffractometer using graphite monochromated 
Mo-K radiation ( = 0.71073 Å) and a Bruker X8 Apex 
diffractometer.. The crystal was cooled and data measured at 
148-150K by an Oxford Cryostream low temperature device.
34
 
The full data sets were recorded and the images processed 
using DENZO and SCALEPACK programs.
35
 Structure solution by 
direct methods was achieved through the use of SHELXS 
programs,
36
 and the structural model refined by full matrix 
least squares on F
2
 using SHELX97 Unless otherwise stated, 
hydrogen atoms were placed using idealised geometric 
positions (with free rotation for methyl groups), allowed to 
move in a “riding model” along with the atoms to which they 
were attached, and refined isotropically. Molecular graphics 
were plotted using OLEX2
37
 and Mercury.
38
 Editing of CIFs and 
construction of tables of bond lengths and angles were 
achieved using WC
39
 and PLATON.
30
  
Chemosensitvity Studies 
In vitro chemosensitivity tests were performed at the 
University of Huddersfield, against HCT116 (human colon 
carcinoma), A2780 (human ovarian carcinoma) and A2780cis 
(cisplatin resistant A2780 cells) cancer cell lines, and against 
ARPE-19 (human retinal epithelial non-cancer) cells. ARPE-19 
cells were obtained from the American Type Culture 
Collection. Cancer cell lines were routinely maintained as 
monolayer cultures in appropriate medium (RPMI 1640 
supplemented with 10% foetal calf serum, sodium pyruvate (1 
mM) and L-glutamine (2 mM) ARPE-19 cells were cultured in 
DMEM-F12 medium containing 10% foetal calf serum. For 
chemosensitivity studies, cells were incubated in 96-well plates 
at a concentration of 2 × 10
3 
cells per well and the plates were 
incubated for 24 hours at 37 °C in an atmosphere of 5% CO2 
prior to drug exposure. Compounds or cisplatin were each 
dissolved in dimethylsulfoxide to provide stock solutions that 
were diluted to provide a range of final concentrations. Drug 
solutions were added to cells (the final DMSO concentrations 
was less than 0.1% (v/v) in all cases) and incubated for 5 days 
at 37°C in an atmosphere of 5% CO2. 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) (20 L, 5 mg mL
−1
) 
was added to each well and incubated for 4 hours at 37°C in an 
atmosphere of 5% CO2. All solutions were then removed by 
pipetting and 150 μL of dimethylsulfoxide added to each well 
in order to dissolve the purple formazan crystals absorbance of 
each well at 540 nm measured by spectrophotometer. Lanes 
containing medium only and 100% cells were used as blanks 
for the spectrophotometer and 100% cell survival respectively. 
Cell survival was determined as the true absorbance of treated 
cells divided by the true absorbance of controls and expressed 
as a percentage. The IC50 values were determined from dose 
response curves of % survival against drug concentration. Each 
experiment was repeated three times and a mean value 
obtained and stated as IC50 (μM) ± SD. 
Induction of Cancer Cell Death by Apoptosis 
HCT116 cells were incubated in T-25 flasks and diluted to 
concentrations of 2.5 x 10
4
 cells/flask (0.5 x 10
4
 cells/ mL) using 
complete RMPI 1640 medium. These were incubated for 24 
hours at 37°C in an atmosphere of 5.0% CO2. Complexes were 
dissolved in dimethylsulfoxide and then further diluted with 
RMPI 1640 to obtained concentrations ranging from 0-60 M. 
The cells were then incubated with the varying concentrations 
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of complex for 72 hours, media/drug solutions were removed 
and flasks were washed with PBS (5 mL), adding all collected 
supernatants to a centrifuge tube. Trypsin (1 mL/flask) was 
added to each flask and then incubated for 5 minutes until a 
single cell suspension was obtained. The trypsin was then 
neutralised with medium (5 mL) and the whole contents of the 
flask transferred to the same centrifuge tube. The tube was 
centrifuged at 1000 rcf for 3-5 minutes, the supernatant 
removed and the pellet re-suspended in PBS (1 mL). The 1 mL 
suspension was transferred to an Eppendorf tube and 
centrifuged at 1500 rpm for 5 minutes. The supernatant was 
removed and the pellet stained with JC-1 in order to stain for 
loss of mitochondrial membrane potential and apoptosis. This 
was performed as per the manufacturer’s protocol 
(Chemometec) and cell samples were analysed using an 
NC3000 flow cytometer (Chemometec). 
Characterisation 
Compound 1. Yield: 72 mg, 0.06 mmol, 86 %. ES-MS (+) 
(MeOH): m/z 501.1 [RuC26H26N2OF]
+
, 581.02 
[RuC26H25N2OFBr]
+
. Anal. Calc.: C 49.8, H 4.2, N 4.7%. Anal. 
Found: C 49.5, H 4.0, N 4.3%. 
1
H NMR: (CD3OD, 500 MHz, 298 
K) δ 8.92 (d, 1H, 
3
J(
1
H-
1
H) = 8.8 Hz, quin), 8.60 (d, 1H, 
3
J(
1
H-
1
H) 
= 8.4 Hz, quin), 8.15-8.04 (m, 3H, quin), 7.89 (td, 2H, 
3
J(
1
H-
1
H) = 
7.9 Hz, 
4
J(
1
H-
19
F) = 0.8 Hz, ar), 7.33-7.30 (m, 2H, ar), 7.23-7.20 
(m, 1H, ar), 5.72 (d, 1H, 
3
J(
1
H-
1
H) = 6.1 Hz, p-cym), 5.58 (d, 1H, 
3
J(
1
H-
1
H) = 5.9 Hz, p-cym), 5.41 (d, 1H, 
3
J(
1
H-
1
H) = 6.1 Hz, p-
cym), 4.81 (d, 1H, 
3
J(
1
H-
1
H) = 5.9 Hz, p-cym), 2.30-2.27 (m, 1H, 
CH(CH3)2), 2.14 (s, 3H, CH3), 0.93 (d, 3H, 
3
J(
1
H-
1
H) = 6.9 Hz, 
CH(CH3)2), 0.80 (d, 3H, 
3
J(
1
H-
1
H) = 6.9 Hz). 
13
C{
1
H} NMR: 
(CD3OD, 125 MHz, 298 K) δ 168.6 (Q, C-O), 158.2 (d, Q, C-F, 
1
J(
13
C-
19
F) = 267.9 Hz), 150.0 (Q), 141.2 (CH, quin), 140.0 (Q), 
132.6 (CH, quin), 131.7 (CH, quin), 131.6 (CH, quin), 130.1 (CH, 
quin), 129.3 (Q), 128.8 (d, CH, 
3
J(
13
C-
19
F) = 7.5 Hz, ar), 128.2 
(CH, ar) 125.6 (CH, ar), 122.5 (CH, quin), 116.9 (d, CH,
 2
J(
13
C-
19
F) 
= 21.4 Hz, ar), 105.4 (Q), 101.7 (Q), 101.4 (Q), 86.7 (CH, p-cym), 
86.4 (CH, p-cym), 85.5 (CH, p-cym), 85.3 (CH, p-cym), 32.4 
(CH(CH3)2), 22.2 (CH(CH3)2), 22.0 (CH(CH3)2), 19.6 (CH3). 
Compound 2. Yield: 39 mg, 0.03 mmol, 36%. ES-MS (+) 
(MeOH): m/z 501.1 [RuC26H24N2OF]
+
. Anal. Calc.: C 50.3, H 4.9, 
N 4.4%. Anal. Found: C 49.2, H 4.7, N 4.7%. 
1
H NMR: (CD3OD, 
500 MHz, 298 K) δ 8.94 (d, 1H, 
3
J(
1
H-
1
H) = 8.9 Hz, quin), 8.61 (d, 
1H, 
3
J(
1
H-
1
H) = 8.4 Hz, quin), 8.14-8.11 (m, 2H, quin), 8.05 (td, 
1H, 
3
J(
1
H-
1
H) = 6.9 Hz, 
4
J(
1
H-
1
H) = 1.6 Hz, quin), 7.87-7.79 (m, 
3H, quin+ar), 7.16 (td, 2H, 
3
J(
1
H-
1
H) = 7.9 Hz, 
3
J(
1
H-
1
H) = 5.1 
Hz), 5.71 (d, 1H, 
3
J(
1
H-
1
H) = 5.9 Hz, p-cym), 5.53 (d, 1H, 
3
J(
1
H-
1
H) = 5.9 Hz, p-cym), 5.41 (d, 1H, 
3
J(
1
H-
1
H) = 5.9 Hz, p-cym), 
4.75 (d, 1H, 
3
J(
1
H-
1
H) = 5.9 Hz, p-cym), 2.31-2.22 (m, 1H, 
CH(CH3)2), 2.22 (s, 3H, CH3), 0.98 (d, 3H, 
3
J(
1
H-
1
H) = 6.9 Hz, 
CH(CH3)2), 0.85 (d, 3H, 
3
J(
1
H-
1
H) = 6.9 Hz, CH(CH3)2). 
13
C{
1
H} 
NMR: (CD3OD, 125 MHz, 298 K) δ 169.1 (Q, C-O), 162.0 (d, Q, 
C-F, 
1
J(
13
C-
19
F) = 241.3 Hz), 158.3 (Q), 150.4 (Q), 149.3 (Q), 
141.6 (CH, quin), 133.0 (CH, quin), 132.0 (CH, quin), 131.6 (CH, 
quin), 130.5 (Q), 130.1 (CH, quin), 129.4 (d, 2 x CH,
 3
J(
13
C-
19
F) = 
7.5 Hz, ar), 123.0 (CH, quin), 116.5 (d, 2 x CH,
 2
J(
13
C-
19
F) = 22.6 
Hz, ar), 105.1 (Q), 102.7 (Q), 87.2 (CH, p-cym), 87.0 (CH, p-
cym), 86.3 (CH, p-cym), 85.8 (CH, p-cym), 32.8 (CH(CH3)2), 22.6 
(CH(CH3)2), 22.5 (CH(CH3)2), 20.1 (CH3). 
Compound 3. Yield: 65 mg, 0.05 mmol, 76%. ES-MS (+) 
(MeOH): m/z 519.1 [RuC26H24N2OF2]
+
. Anal. Calc.: C 48.4, H 
4.0, N 4.3%. Anal. Found: C 48.9, H 3.8, N 4.4%. 
1
H NMR: 
(CD3OD, 500 MHz, 298 K) δ 8.92 (d, 1H, 
3
J(
1
H-
1
H) = 8.8 Hz, 
quin), 8.61 (d, 1H, 
3
J(
1
H-
1
H) = 8.4 Hz, quin), 8.14 (dd, 1H, 
3
J(
1
H-
1
H) = 8.2 Hz, 
4
J(
1
H-
1
H) = 1.5 Hz, quin), 8.10 (d, 1H, 
3
J(
1
H-
1
H) = 
8.4 Hz, quin), 8.05 (td, 1H, 
3
J(
1
H-
1
H) = 7.2 Hz, 
4
J(
1
H-
1
H) = 1.5 Hz, 
quin), 7.94-7.84 (m, 2H, quin+ar), 7.15 (td, 1H, 
3
J(
1
H-
1
H) = 8.9 
Hz, 
3
J(
1
H-
19
F) = 2.6 Hz, ar), 6.99 (td, 1H, 
3
J(
1
H-
1
H) = 8.0 Hz, 
4
J(
1
H-
1
H) = 1.4 Hz, ar), 5.72 (d, 1H, 
3
J(
1
H-
1
H) = 6.1 Hz, p-cym), 5.58 (d, 
1H, 
3
J(
1
H-
1
H) = 5.9 Hz, p-cym), 5.43 (d, 1H, 
3
J(
1
H-
1
H) = 6.1 Hz, p-
cym), 4.80 (d, 1H, 
3
J(
1
H-
1
H) = 5.9 Hz, p-cym), 2.30-2.25 (m, 1H, 
CH(CH3)2), 2.22 (s, 3H, CH3), 0.93 (d, 3H, 
3
J(
1
H-
1
H) = 6.9 Hz, 
CH(CH3)2), 0.81 (d, 3H, 
3
J(
1
H-
1
H) = 6.9 Hz, CH(CH3)2). 
13
C{
1
H} 
NMR: (CD3OD, 125 MHz, 298 K) δ 169.0 (Q, C-O), 161.9 (d, 2 x 
Q, C-F, 
1
J(
13
C-
19
F) = 233.9 Hz) 157.1 (Q), 150.0 (Q), 141.3 (CH, 
quin), 132.6 (2 x CH, quin), 131.8 (CH, quin), 131.2 (CH, quin), 
130.1 (d, CH,
 3
J(
13
C-
19
F) = 18.9 Hz, ar), 122.5 (CH, quin), 112.3 
(d, CH,
 2
J(
13
C-
19
F) = 25.2 Hz, ar), 105.0 (d, CH,
 2
J(
13
C-
19
F) = 61.6 
Hz, ar), 104.3 (Q), 101.7 (Q), 88.7 (CH, p-cym), 86.0 (CH, p-
cym), 85.6 (CH, p-cym), 85.2 (CH, p-cym), 32.5 (CH(CH3)2), 22.2 
(CH(CH3)2), 22.0 (CH(CH3)2), 19.6 (CH3). 
Compound 4. Yield: 82 mg, 0.06 mmol, 83%. ES-MS (+) 
(MeOH): m/z 501.091 [RuC26H25N2OF]
+
. Anal.
 
Calc.: C 47.8, H 
3.8, N 4.3%. Anal.
 
Found: C 47.3, H 3.9, N 4.6%. 
1
H NMR: 
(CD3OD, 500 MHz, 298 K) δ 8.92 (d, 1H, 
3
J(
1
H-
1
H) = 8.8 Hz, 
quin), 8.60 (d, 1H, 
3
J(
1
H-
1
H) = 8.4 Hz, quin), 8.15-8.04 (m, 3H, 
quin), 7.89 (td, 2H, 
3
J(
1
H-
1
H) = 7.9 Hz, 
5
J(
1
H-
1
H) = 0.8 Hz, 
quin+ar), 7.33-7.30 (m, 2H, ar), 7.23-7.20 (m, 1H, ar), 5.74 (d, 
1H, 
3
J(
1
H-
1
H) = 6.0 Hz, p-cym), 5.60 (d, 1H, 
3
J(
1
H-
1
H) = 6.0 Hz, p-
cym), 5.49 (d, 1H, 
3
J(
1
H-
1
H) = 6.3 Hz, p-cym), 4.83 (d, 1H, 
3
J(
1
H-
1
H) = 6.3 Hz, p-cym), 2.33-2.24 (m, 1H, CH(CH3)2), 2.06 (s, 3H, 
CH3), 0.97 (d, 3H, 
3
J(
1
H-
1
H) = 6.9 Hz, CH(CH3)2), 0.82 (d, 3H, 
3
J(
1
H-
1
H) = 6.9 Hz, CH(CH3)2). 
13
C{
1
H} NMR: (CD3OD, 125 MHz, 
298 K) δ 168.7 (Q, C-O), 158.4 (d, Q, C-F, 
1
J(
13
C-
19
F) = 249.0 Hz), 
152.2 (Q), 149.7 (Q), 141.5 (CH, quin), 140.0 (Q), 132.9 (CH, 
quin), 131.8 (CH, quin), 130.6 (CH, quin), 130.1 (CH, quin), 
128.8 (d, CH,
 3
J(
13
C-
19
F) = 7.5 Hz, ar), 128.2 (CH, ar), 125.7 (CH, 
ar), 122.4 (CH, quin), 116.9 (d, CH,
 2
J(
13
C-
19
F) = 21.3 Hz, ar), 
104.4 (Q), 102.7 (Q), 102.0 (Q), 86.8 (CH, p-cym), 86.0 (CH, p-
cym), 85.7 (CH, p-cym), 85.4 (CH, p-cym), 32.3 (CH(CH3)2) 22.2 
(CH(CH3)2), 22.0 (CH(CH3)2), 18.9 (CH3).  
Compound 5. Yield: 77 mg, 0.06 mmol, 69%. ES-MS (+) 
(MeOH): m/z 501.1 [RuC26H25N2OF]
+
. Anal. Calc.: C 47.5, H 3.8, 
N 4.3%. Anal. Found: C 47.2, H 3.7, N 5.2%. 
1
H NMR: (CD3OD, 
500 MHz, 298 K) δ 8.93 (d, 1H, 
3
J(
1
H-
1
H) = 8.8 Hz, quin), 8.62 (d, 
1H, 
3
J(
1
H-
1
H) = 8.3 Hz, quin), 8.13 (t, 2H, 
3
J(
1
H-
1
H) = 6.9 Hz, 
quin), 8.07 (td, 1H, 
3
J(
1
H-
1
H) = 6.9 Hz, 
4
J(
1
H-
1
H) = 1.4 Hz, quin), 
7.86 (td, 1H, 
3
J(
1
H-
1
H) = 6.9 Hz, 
4
J(
1
H-
1
H) = 1.4 Hz, quin), 7.77-
7.74 (m, 2H, ar), 7.17 (t, 2H, 
3
J(
1
H-
1
H) = 6.8 Hz, ar), 5.71 (d, 1H, 
3
J(
1
H-
1
H) = 6.1 Hz, p-cym), 5.52 (d, 1H, 
3
J(
1
H-
1
H) = 5.9 Hz, p-
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cym), 5.45 (d, 1H, 
3
J(
1
H-
1
H) = 6.1 Hz, p-cym), 4.78 (d, 1H, 
3
J(
1
H-
1
H) = 5.9 Hz, p-cym), 2.25-2.22 (m, 1H, CH(CH3)2), 2.13 (s, 3H, 
CH3), 0.98 (d, 3H, 
3
J(
1
H-
1
H) = 6.9 Hz, CH(CH3)2), 0.84 (d, 3H, 
3
J(
1
H-
1
H) = 6.9 Hz, CH(CH3)2). 
13
C{
1
H} NMR (CD3OD, 125 MHz, 
298 K) δ 168.8 (Q, C-O), 161.4 (d, Q, C-F, 
1
J(
13
C-
19
F) = 238.9 Hz), 
158.2 (Q), 149.7 (Q), 148.8 (Q) 141.4 (CH, quin), 132.8 (CH, 
quin), 131.7 (CH, quin), 131.2 (CH, quin), 130.5 (Q), 130.1 (CH, 
quin), 128.8 (d, 2 x CH,
 3
J(
13
C-
19
F) = 7.5 Hz, ar), 122.5 (CH, quin), 
116.1 (d, 2 x CH,
 2
J(
13
C-
19
F) = 22.7 Hz, ar), 103.6 (Q), 102.9 (Q), 
87.0 (CH, p-cym), 86.7 (CH, p-cym), 85.5 (CH, p-cym), 85.4 (CH, 
p-cym), 32.3 (CH(CH3)2), 22.2 (CH(CH3)2), 22.0 (CH(CH3)2), 18.9 
(CH3). 
Compound 6. Yield: 84 mg, 0.06 mmol, 79%. ES-MS (+) 
(MeOH): m/z 519.1 [RuC26H24N2OF2]
+
. Anal. Calc.: C 45.3, H 
4.6, N 3.9%. Anal. Found: C 45.0, H 4.8, N 4.4%. 
1
H NMR: 
(CD3OD, 500 MHz, 298 K) δ 8.92 (d, 1H, 
3
J(
1
H-
1
H) = 8.8 Hz, 
quin), 8.61 (d, 1H, 
3
J(
1
H-
1
H) = 8.4 Hz, quin), 8.14 (dd, 1H, 
3
J(
1
H-
1
H) = 8.2 Hz, 
4
J(
1
H-
1
H) = 1.5 Hz, quin), 8.10 (d, 1H, 
3
J(
1
H-
1
H) = 
8.4 Hz), 8.05 (td, 1H, 
3
J(
1
H-
1
H) = 7.2 Hz, 
4
J(
1
H-
13
C) = 1.5 Hz, 
quin), 7.97-7.84 (m, 2H, quin+ar). 7.15 (td, 1H, 
3
J(
1
H-
1
H) = 8.9 
Hz, 
3
J(
1
H-
19
F) = 2.6 Hz, ar), 6.99 (td, 1H, 
3
J(
1
H-
1
H) = 8.0 Hz, 
4
J(
1
H-
13
F) = 1.4 Hz, ar), 5.72 (d, 1H, 
3
J(
1
H-
1
H) = 6.1 Hz, p-cym), 5.58 (d, 
1H, 
3
J(
1
H-
1
H) = 5.9 Hz, p-cym), 5.43 (d, 1H, 
3
J(
1
H-
1
H) = 6.1 Hz, p-
cym), 4.80 (d, 1H, 
3
J(
1
H-
1
H) = 5.9 Hz, p-cym), 2.30-2.25 (m, 1H, 
CH(CH3)2, p-cym), 2.07 (s, 3H, CH3), 0.93 (d, 3H, 
3
J(
1
H-
1
H) = 6.9 
Hz, CH(CH3)2), 0.81 (d, 3H, 
3
J(
1
H-
1
H) = 6.9 Hz, CH(CH3)2); 
13
C{
1
H} 
NMR: (CD3OD, 125 MHz, 298 K) δ 169.0 (Q, C-O), 162.8 (d, Q, 
C-F, 
1
J(
13
C-
19
F) = 244.0 Hz), 160.9 (d, Q, C-F, 
1
J(
13
C-
19
F) = 244.0 
Hz), 157.1 (Q), 150.0 (Q), 141.3 (CH, quin), 134.7 (Q), 132.6 (2 x 
CH, quin), 131.8 (CH, quin), 131.2 (CH, quin), 130.0 (d, CH, 
3
J(
13
C-
19
F) = 18.9 Hz, ar), 128.0 (Q), 122.5 (CH, quin), 112.3 (d, 
CH,
 2
J(
13
C-
19
F) = 25.2 Hz, ar), 105.0 (d, CH,
 2
J(
13
C-
19
F) = 61.6 Hz, 
ar), 101.7 (Q), 101.4 (Q), 88.7 (CH, p-cym), 86.0 (CH, p-cym), 
85.6 (CH, p-cym), 85.2 (CH, p-cym), 32.2 (CH(CH3)2), 22.2 
(CH(CH3)2), 22.0 (CH(CH3)2), 19.6 (CH3). 
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